DeFect cLOsure After Colonic ESD With underwaTer Technique
Launched by CHINESE UNIVERSITY OF HONG KONG · Dec 28, 2019
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
Endoscopic submucosal dissection (ESD) is a minimally invasive technique that has been increasingly applied to superficial colorectal tumours over the past two decades (1, 2). Although serious complications with this procedure are uncommon, both significant delayed haemorrhage (1-2%) and perforation (4-6%) are recognised complications (3). Although perforation is generally recognised and treated at time of endoscopy, delayed bleeding often requires repeat readmission and endoscopy for haemorrhage control. There is growing evidence to support prophylactic clip closure of mucosal defects to r...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing elective endoscopic resection
- • Colorectal superficial neoplasm with a resultant mucosal defect of ≥20mm
- • Age \>18 years old
- Exclusion Criteria:
- • Patients on anticoagulation (Warfarin or other direct oral anticoagulants)
- • Muscular perforation during the endoscopic resection
- • Incomplete endoscopic resection
- • Lesions arising from surgical anastomotic site
- • Marked electrolyte abnormalities
- • Other cases deemed by the examining physician as unsuitable for safe treatment
- • Patients who refused to participate
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Hon Chi Yip, MBChB
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials